SNAP-8 (Acetyl Octapeptide-3)
Overview
SNAP-8 is Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH₂), a longer relative of Argireline. It keeps the same core sequence and adds two residues (Ala-Asp) at the C-terminus, a change studied for stronger interaction with the SNARE complex. Like Argireline it is researched as a topical neuromodulatory peptide for dynamic expression lines, and is frequently positioned as a second-generation analogue.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 868802-72-6 |
| INCI name | Acetyl Octapeptide-3 |
| Amino-acid sequence | Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ |
| One-letter code | Ac-EEMQRRAD-NH₂ |
| Molecular formula | C₄₃H₇₃N₁₅O₁₆S |
| Molecular weight | 1074.30 g/mol |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white lyophilized powder |
- Class
- Neuromodulatory peptide (SNARE inhibitor)
- Relationship
- Extended-sequence Argireline analogue
- Research status
- Clinical research
- Typical route
- Topical
- Reference trade name
- SNAP-8™ (Lipotec)
- Key feature
- Two extra C-terminal residues (Ala-Asp)
Mechanism of Action
SNAP-8 is studied on the same principle as Argireline — interfering with SNARE assembly to soften acetylcholine release at the neuromuscular junction — but the two additional C-terminal residues are investigated for a tighter interaction with the SNAP-25 region, which is the rationale usually given for calling it a second-generation peptide.
| Component | Research description |
|---|---|
| Primary target | SNARE assembly (SNAP-25 / syntaxin / VAMP) |
| Inhibition mode | Studied as competitive binding at the SNAP-25 N-terminal region, with reportedly higher affinity than the hexapeptide |
| Extended sequence | The added Ala-Asp is investigated for improved receptor interaction |
| Neurotransmitter | Associated with reduced acetylcholine exocytosis |
| Selectivity | Reported to act on regulated exocytosis rather than constitutive secretion |
Comparison with Argireline (sequence-level facts):
| Parameter | Argireline | SNAP-8 |
|---|---|---|
| Sequence | Ac-EEMQRR-NH₂ | Ac-EEMQRRAD-NH₂ |
| Length | 6 residues | 8 residues |
| Molecular weight | 888.5 Da | 1074.3 Da |
| Reported binding | Baseline | Higher affinity (extended sequence) |
Pharmacology
| Parameter | Value |
|---|---|
| logP | −1.9 (hydrophilic) |
| pKa | ≈ 12.5 (arginine guanidinium), 4.0 (Glu / Asp) |
| Topical bioavailability | ~2–5% (usually needs liposomal or enhancer delivery) |
| Stability | High — capped N-acetyl and C-amide ends |
| Protein binding | Low to moderate |
| Metabolism | Proteolytic breakdown in the epidermis |
| Route of administration | Topical |
Research Evidence
SNAP-8 is studied as a second-generation neuromodulatory peptide, usually against Argireline as the reference, in both mechanistic (preclinical) and human (clinical) work.
Advanced expression-line research
Studied where a stronger neuromodulatory effect than the hexapeptide is the goal.
Structure–activity studies
A useful case for how sequence length changes SNARE interaction in the EEMQRR family.
Formulation research
Investigated for delivery of a larger, hydrophilic peptide across the skin barrier.
Combination research
Explored alongside matrikine peptides for multi-mechanism formulations.
Preclinical research — representative models and what they investigate:
| Model | Research focus | Reference |
|---|---|---|
| Competitive binding assay | SNARE-assembly interference vs the hexapeptide | Schagen SK (2017, review) |
| Nerve–muscle preparation | Muscle-contraction amplitude | Gorouhi F, Maibach HI (2009) |
| Neuronal cell model | Stimulated neurotransmitter release | Schagen SK (2017, review) |
| Human skin (ex vivo) | Peptide penetration | Lupo MP, Cole AL (2007) |
Clinical research — the types of human study in which the ingredient is examined:
| Study type | Endpoints studied | Reference |
|---|---|---|
| Topical serum / cream | Expression-line and crow’s-feet appearance | Gorouhi F, Maibach HI (2009) |
| Anti-aging formulations | Overall wrinkle severity | Schagen SK (2017) |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Reduced muscle-contraction amplitude (enhanced SNARE inhibition vs Argireline) | neuromuscular models | SNAP-8 literature |
| Reduction in expression-line appearance | topical human study | Gorouhi F, Maibach HI (2009) |
For laboratory research and cosmetic formulation study only. Descriptions refer to published research contexts and are not product or health claims.
Formulation & Dosing Reference
| Parameter | Value |
|---|---|
| Typical topical concentration | 1–10% (w/w) |
| Common working range | 5–10% |
| Solubility in water | ≥ 50 mg/mL |
| Solubility in DMSO | ≥ 50 mg/mL |
| Recommended formulation pH | 5.0–7.0 |
| Storage (powder) | 2–8°C, sealed, dry, protected from light |
Safety Profile
| Assessment | Reported result |
|---|---|
| Acute oral toxicity (rat) | LD50 > 2000 mg/kg |
| Dermal irritation (rabbit) | Non-irritant at 10% |
| Ocular irritation (rabbit) | Non-irritant |
| Skin sensitization (GPMT) | Non-sensitizing |
| Mutagenicity (Ames) | Negative |
| INCI status | Approved cosmetic ingredient (Acetyl Octapeptide-3) |
Physicochemical Properties
| Property | Value |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility in water | ≥ 50 mg/mL |
| Solubility in DMSO | ≥ 50 mg/mL |
| Melting point | > 200°C (decomposition) |
| pH (1% aqueous) | 5.0–6.0 |
| Isoelectric point (pI) | ≈ 8.5 |
| Net charge at pH 7 | ≈ +1 |
| Light sensitivity | Low |
Synthesis & Manufacturing
SNAP-8 is made by solid-phase peptide synthesis of the eight-residue sequence on an amide resin, with N-terminal acetylation. The longer chain and the Arg-Arg motif make coupling efficiency the main thing to optimise, and the methionine is protected against oxidation the same way as in Argireline.
| Step | Detail |
|---|---|
| Strategy | Solid-phase peptide synthesis, Fmoc/tBu chemistry |
| Resin | Rink amide MBHA resin (C-terminal amide) |
| Coupling | HATU / HBTU with DIPEA; double coupling for hindered residues |
| Side-chain protection | Glu(OtBu), Gln(Trt), Arg(Pbf), Asp(OtBu); Met unprotected |
| N-terminal acetylation | Acetic anhydride / DIPEA after final Fmoc removal |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5), with scavengers |
| Purification | Preparative RP-HPLC (C18, TFA/ACN gradient) |
- Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
- Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
- Critical quality attributes: correct molecular weight and low deletion-peptide content. Aspartimide formation at the aspartate and oxidation of the methionine are the main solution-phase degradation routes.
Analytical Methods
| Method | Parameter | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| HPLC retention | C18, 5–30% B over 20 min | Single main peak |
| ESI-MS (positive mode) | Identity / mass | [M+H]⁺ ≈ 1075 Da |
| MALDI-TOF | Mass confirmation | [M+H]⁺ ≈ 1075 Da |
| Amino-acid analysis | Composition | Consistent with the stated sequence |
| LC-MS (extracted ion) | Deletion-peptide impurities | Within specification |
| Karl Fischer | Water content | < 6% |
| LAL assay | Endotoxin | Within specification |
| Ion chromatography | Residual TFA | < 500 ppm |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: 5–30% B over 20 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
- Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 1075 Da). Aspartimide formation at the aspartate and oxidation of the methionine are the main solution-phase degradation routes.
Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized, −20°C, dark | ≥ 24 months | No significant degradation (purity > 97%) |
| Lyophilized, 25°C, dark | ≥ 12 months | < 2% degradation |
| Aqueous solution pH 5.5, 4°C | 7–14 days | Minor degradation |
| Aqueous solution pH 5.5, 25°C | 7 days | < 5% degradation |
| Formulated serum / cream (25°C) | 12+ months | Peptide largely retained |
| Light exposure (ICH Q1B) | 1.2 M lux·h | Light-stable |
| Freeze–thaw | 3 cycles | Acceptable |
| pH stress (pH 3 or pH 8) | 7 days | Faster degradation outside pH 5–7 |
- Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
- Minimise freeze-thaw cycles; aliquot material used across many sessions.
- Key factor: Aspartimide formation at the aspartate and oxidation of the methionine are the main solution-phase degradation routes.
Selected References
Representative peer-reviewed literature on neuromodulatory cosmetic peptides. Listed for research reference.
- Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science, 2002.
- Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 2009.
- Lupo MP, Cole AL. Cosmeceutical peptides. Dermatologic Therapy, 2007.
- Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics, 2017.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS; end-group modifications verified
- Research samples through to bulk, with worldwide delivery
- Custom sequences and packaging on request
Need SNAP-8 — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
